Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth Silkenstedt

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Hematological Oncology|June 9, 2023
Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approachesElisabeth Silkenstedt, Martin Dreyling
Blood|July 26, 2024
Treatment of relapsed/refractory MCLElisabeth Silkenstedt, Martin Dreyling
Hematological Oncology|June 9, 2021
Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approachesElisabeth Silkenstedt, Martin Dreyling
Deutsche Medizinische Wochenschrift (1946)|November 1, 2022
[Aggressive lymphoma (DLBCL, MCL) - what's new?]Elisabeth Silkenstedt, Martin Dreyling
British Journal of Haematology|March 30, 2021
Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approachesElisabeth Silkenstedt, Kim Linton, Martin Dreyling
Lancet (London, England)|April 13, 2024
B-cell non-Hodgkin lymphomasElisabeth Silkenstedt, Gilles Salles, Elias Campo, et al.
Blood Advances|May 15, 2024
Biological and clinical determinants shaping heterogeneity in mantle cell lymphomaCristina López, Elisabeth Silkenstedt, Martin Dreyling, et al.
Journal of Hematology & Oncology|September 6, 2018
Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXASimon Heine, Markus Kleih, Neus Giménez, et al.
Hematological Oncology|June 10, 2023
Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimusMarie Moosburner, Lamija Alibegovic, Korbinian Hasselmann, et al.
Blood Advances|February 21, 2025
BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphomaKatja Gutmair, Diego Villa, Nicholas Cunningham, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Hematological Oncology|June 9, 2023
Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approachesElisabeth Silkenstedt, Martin Dreyling
Blood|July 26, 2024
Treatment of relapsed/refractory MCLElisabeth Silkenstedt, Martin Dreyling
Hematological Oncology|June 9, 2021
Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approachesElisabeth Silkenstedt, Martin Dreyling
Deutsche Medizinische Wochenschrift (1946)|November 1, 2022
[Aggressive lymphoma (DLBCL, MCL) - what's new?]Elisabeth Silkenstedt, Martin Dreyling
British Journal of Haematology|March 30, 2021
Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approachesElisabeth Silkenstedt, Kim Linton, Martin Dreyling
Lancet (London, England)|April 13, 2024
B-cell non-Hodgkin lymphomasElisabeth Silkenstedt, Gilles Salles, Elias Campo, et al.
Blood Advances|May 15, 2024
Biological and clinical determinants shaping heterogeneity in mantle cell lymphomaCristina López, Elisabeth Silkenstedt, Martin Dreyling, et al.
Journal of Hematology & Oncology|September 6, 2018
Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXASimon Heine, Markus Kleih, Neus Giménez, et al.
Hematological Oncology|June 10, 2023
Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimusMarie Moosburner, Lamija Alibegovic, Korbinian Hasselmann, et al.
Blood Advances|February 21, 2025
BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphomaKatja Gutmair, Diego Villa, Nicholas Cunningham, et al.
Pageof 2